[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Hanna E, DeMonte F, Ibrahim S, Roberts D, Levine N, Kupferman M: Endoscopic resection of sinonasal cancers with and without craniotomy: oncologic results. Arch Otolaryngol Head Neck Surg; 2009 Dec;135(12):1219-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the oncologic outcomes of patients with sinonasal cancer treated with endoscopic resection.
  • SETTING: Tertiary care academic cancer center.
  • PATIENTS: All patients with biopsy-proved malignant neoplasm of the sinonasal region who were treated with endoscopic resection between 1992 and 2007 were included in the study, and their charts were reviewed for demographics, histopathologic findings, treatment details, and outcome.
  • Of the 120 patients, 41% presented with previously untreated disease, 46% presented with persistent disease that had been partially resected, and 13% presented with recurrent disease after prior treatment.
  • The primary T stage was evenly distributed across all patients as follows: T1, 25%; T2, 25%; T3, 22%; and T4, 28%.
  • However, the T-stage distribution was significantly different between the EEA group and the CEA group.
  • Approximately two-thirds (63%) of the patients treated with EEA had a lower (T1-2) disease stage, while 95% of patients treated with CEA had a higher (T3-4) disease stage (P < .001).
  • The most common tumor types were esthesioneuroblastoma (17%), sarcoma (15%), adenocarcinoma (14%), melanoma (14%), and squamous cell carcinoma (13%).
  • Other, less common tumors included adenoid cystic carcinoma (7%), neuroendocrine carcinoma (4%), and sinonasal undifferentiated carcinoma (2%).
  • Of the 120 patients, 50% were treated with surgery alone, 37% received postoperative radiation therapy, and 13% were treated with surgery, radiation therapy, and chemotherapy.
  • Our results suggest that, in well-selected patients and with appropriate use of adjuvant therapy, endoscopic resection of sinonasal cancer results in acceptable oncologic outcomes.
  • [MeSH-major] Endoscopy. Paranasal Sinus Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Child. Craniotomy. Disease-Free Survival. Esthesioneuroblastoma, Olfactory / surgery. Ethmoid Sinus. Female. Humans. Male. Melanoma / surgery. Middle Aged. Neoplasm Recurrence, Local. Nose Neoplasms / mortality. Nose Neoplasms / surgery. Radiotherapy, Adjuvant. Retrospective Studies. Sarcoma / surgery


2. Hoppe BS, Nelson CJ, Gomez DR, Stegman LD, Wu AJ, Wolden SL, Pfister DG, Zelefsky MJ, Shah JP, Kraus DH, Lee NY: Unresectable carcinoma of the paranasal sinuses: outcomes and toxicities. Int J Radiat Oncol Biol Phys; 2008 Nov 1;72(3):763-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unresectable carcinoma of the paranasal sinuses: outcomes and toxicities.
  • PURPOSE: To evaluate long-term outcomes and toxicity in patients with unresectable paranasal sinus carcinoma treated with radiotherapy, with or without chemotherapy.
  • METHODS AND MATERIALS: Between January 1990 and December 2006, 39 patients with unresectable Stage IVB paranasal sinus carcinoma were treated definitively with chemotherapy plus radiotherapy (n = 35, 90%) or with radiotherapy alone (n = 4, 10%).
  • Patients were treated with three-dimensional conformal radiotherapy (n = 18, 46%), intensity-modulated radiotherapy (n = 12, 31%), or conventional radiotherapy (n = 9, 23%) to a median treatment dose of 70 Gy.
  • Most patients received concurrent platinum-based chemotherapy (n = 32, 82%) and/or concomitant boost radiotherapy (n = 29, 74%).
  • Nine patients developed neck relapses; however none of the 4 patients receiving elective neck irradiation had a nodal relapse.
  • In 13 patients acute Grade 3 mucositis developed.
  • Severe late toxicities occurred in 2 patients with radionecrosis and 1 patient with unilateral blindness 7 years after intensity-modulated radiation therapy (77 Gy to the optic nerve).
  • The only significant factor for improved local progression-free survival and overall survival was a biologically equivalent dose of radiation >/=65 Gy.
  • CONCLUSIONS: Treatment outcomes for unresectable paranasal sinus carcinoma are poor, and combined-modality treatment is needed that is both more effective and associated with less morbidity.
  • [MeSH-major] Nose Neoplasms / radiotherapy. Paranasal Sinus Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Patient Selection. Platinum Compounds / therapeutic use. Radiotherapy Dosage. Radiotherapy, Conformal / methods. Radiotherapy, Intensity-Modulated / methods. Survival Analysis. Survivors. Young Adult

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18395361.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Platinum Compounds
  •  go-up   go-down


3. Paiva MB, Bublik M, Castro DJ, Udewitz M, Wang MB, Kowalski LP, Sercarz J: Intratumor injections of cisplatin and laser thermal therapy for palliative treatment of recurrent cancer. Photomed Laser Surg; 2005 Dec;23(6):531-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intratumor injections of cisplatin and laser thermal therapy for palliative treatment of recurrent cancer.
  • OBJECTIVE: The aim of this work was to report initial findings on the clinical application of intratumor injection of cisplatin in a gel (CDDP/gel) combined with laser-induced thermal therapy (LITT) for cancer treatment in a single patient with advanced stage disease.
  • BACKGROUND DATA: LITT with the neodymium:yttriumaluminum- garnet (Nd:YAG) laser via fiberoptics is a precise, minimally invasive alternative for thermoablation of unresectable or recurrent head and neck neoplasms, but recurrence is often seen at the treatment margins.
  • Combining intratumor chemotherapy with interstitial laser should be most effective using drugs with thermally enhanced toxicity, such as cisplatin.
  • The CDDP/gel therapeutic implant was expected to retain a higher concentration of cisplatin in the tumor margins for improved LITT treatment of the patient presented.
  • METHODS: In this case report, the cisplatin dose was 0.25 mL gel/cm(3) tumor volume (20 mg of CDDP) followed by LITT (Nd:YAG laser, 50 W, PD = 2,200 J/cm(2)) after the chemotherapy session.
  • RESULTS: The patient responded with local tumor eradication, and no signs of systemic toxicity were observed related to this therapy.
  • However, the patient developed progressive metastatic disease in the lungs and died 2.5 months later.
  • Based on preclinical evidence obtained at UCLA and the results of this study, we are encouraged to continue our refinement of LITT combined with chemotherapy for cancer treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Laser Therapy. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Aged. Ethmoid Sinus. Female. Fiber Optic Technology. Humans. Injections, Intralesional. Melanoma / therapy. Palliative Care. Paranasal Sinus Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16356142.001).
  • [ISSN] 1549-5418
  • [Journal-full-title] Photomedicine and laser surgery
  • [ISO-abbreviation] Photomed Laser Surg
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K23 CA 88921
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


Advertisement
4. Kamiński B, Kobiorska-Nowak J, Bień S: [Distant metastases to nasal cavities and paranasal sinuses, from the organs outside the head and neck]. Otolaryngol Pol; 2008;62(4):422-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Distant metastases to nasal cavities and paranasal sinuses, from the organs outside the head and neck].
  • At that time, the correct diagnosis requires only to compare the pathology report from the primary biopsy, with the biopsy from the lump in the head and neck.
  • The metastases to nasal cavity and paranasal sinuses are very rare and usually localized within the maxillary sinus.
  • MATERIAL: 4 cases, out of 46 all distant metastases to the head and neck region, localized in the nasal cavity and paranasal sinuses, diagnosed and treated in Dept. of ORL H&N surgery, Holy Cross Cancer Centre, from 2001 to 2007.
  • Case I. F. 71 years; the metastasis of colonic carcinoma to the sphenoid sinus as a first symptom of the disease).
  • The palliative Rtg-therapy was applied, and patient died in 2 months after diagnosis was established.
  • Case II. M. 69 y with metastasis of kidney cancer (Ca clarocellulare) to the nasal cavity, during a palliative stage of the disease due to multiple lung metastases.
  • Patient was treated with multiple courses of chemotherapy due to generalization of the disease.
  • Cases III. F. 50 years in palliative stage of the breast cancer, with metastases to the bones and hepar and with metastasis to the maxillary sinus.
  • Received palliative Rtg. therapy on the region of metastasis.
  • Died in 5 months after diagnosis of maxillary sinus metastasis.
  • Case IV. F. 54 years in palliative stage of the colonic cancer, with multiple metastases to the lungs and hepar; with metastasis to the maxillary sinus.
  • During hemotherapy a symptoms of tumor of the maxillary sinus appeared, confirmed as a metastasis.
  • The palliative Rtg-therapy on the region of metastasis.
  • Died in 18 months, after diagnosis of maxillary sinus metastasis.
  • CONCLUSIONS: The prognosis of metastases from distant organs, to the nasal cavity and paranasal sinuses is miserable.
  • In the majority of distant metastases to the nose and paranasal sinuses, the palliative therapy is the only possible option of treatment.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Carcinoma, Renal Cell / pathology. Colonic Neoplasms / pathology. Paranasal Sinus Neoplasms / secondary. Skull Base Neoplasms / secondary
  • [MeSH-minor] Aged. Female. Humans. Male. Middle Aged. Poland. Prognosis. Survival Analysis. Treatment Failure

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18837216.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


5. Ma HH, Qian LT, Pan HF, Yang L, Zhang HY, Wang ZH, Ma J, Zhao YF, Gao J, Wu AD: Treatment outcome of radiotherapy alone versus radiochemotherapy in early stage nasal natural killer/T-cell lymphoma. Med Oncol; 2010 Sep;27(3):798-806
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment outcome of radiotherapy alone versus radiochemotherapy in early stage nasal natural killer/T-cell lymphoma.
  • This study aims to investigate the prognostic factors and long-term treatment outcome in patients with early stage nasal natural killer (NK)/T-cell lymphoma.
  • Early stage (stage IE: 51, stage IIE: 13) nasal NK/T-cell lymphoma (NNTCL) was established according to Ann Arbor staging classification.
  • Results show that the median overall survival (OS) time was 41 months.
  • There is no significant difference between two treatment modalities.
  • Multivariate analysis showed that Eastern Cooperative Oncology Group performance status (PS) score > or = 2, local tumor invasion out of nasal cavity, and lower complete remission (CR) rates in the initial treatment were significant unfavorable independent prognostic factors.
  • Taken together, our study suggests that RCT did not improve the survival rate of patients with early stage NNTCL.
  • PS score before treatment, local tumor invasion out of nasal cavity, and CR rate of the primary treatment may be independent prognostic factors among the subtype lymphoma entity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Extranodal NK-T-Cell / drug therapy. Nose Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Chemotherapy, Adjuvant. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Mitoxantrone / administration & dosage. Paranasal Sinus Neoplasms / drug therapy. Paranasal Sinus Neoplasms / radiotherapy. Prednisolone / administration & dosage. Prednisone / administration & dosage. Radioisotope Teletherapy. Radiotherapy, High-Energy. Treatment Outcome. Vincristine / administration & dosage. Young Adult

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] Blood. 2004 Jan 1;103(1):216-21 [12933580.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Ann Oncol. 2001 Mar;12(3):349-52 [11332147.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):54-63 [10623693.001]
  • [Cites] Cancer. 1996 May 15;77(10):2137-49 [8640683.001]
  • [Cites] Am J Surg Pathol. 1999 Nov;23(11):1356-69 [10555004.001]
  • [Cites] Leuk Lymphoma. 2006 Jul;47(7):1274-82 [16923557.001]
  • [Cites] Acta Oncol. 1997;36(3):307-11 [9208902.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Apr;20(4):797-802 [2004957.001]
  • [Cites] Hum Pathol. 1999 Jul;30(7):849-55 [10414505.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):666-70 [7884427.001]
  • [Cites] Radiother Oncol. 1996 Jan;38(1):1-6 [8850419.001]
  • [Cites] Br J Cancer. 2005 Apr 11;92(7):1226-30 [15798768.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):181-9 [16382127.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Sep;15(3):599-605 [3417488.001]
  • [Cites] Clin Lab Haematol. 2000 Aug;22(4):215-20 [11012633.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4124-30 [18626005.001]
  • [Cites] Int J Surg Pathol. 2004 Oct;12(4):375-87 [15494863.001]
  • [Cites] Oncol Rep. 2005 Feb;13(2):265-71 [15643509.001]
  • [Cites] Am J Surg Pathol. 1996 Jan;20(1):103-11 [8540601.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):31-8 [17049184.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3785-90 [16109779.001]
  • [Cites] Hematol Oncol. 1992 May-Aug;10(3-4):141-7 [1398510.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):182-90 [12182990.001]
  • [Cites] Am J Surg Pathol. 2000 Nov;24(11):1511-7 [11075852.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Cancer. 1998 Aug 15;83(4):806-12 [9708949.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2095-105 [11733360.001]
  • [Cites] Leukemia. 2001 Jul;15(7):1123-6 [11455983.001]
  • [Cites] Ann Oncol. 2004 Oct;15(10):1467-75 [15367405.001]
  • [Cites] Acta Oncol. 2001;40(1):19-23 [11321654.001]
  • [Cites] Radiother Oncol. 2001 Dec;61(3):261-9 [11730995.001]
  • [Cites] Cancer. 1998 Aug 1;83(3):449-56 [9690537.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):70-7 [9440725.001]
  • (PMID = 19685292.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Controlled Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; BZ114NVM5P / Mitoxantrone; VB0R961HZT / Prednisone; CHOP-B protocol; MCOP protocol; VAP-cyclo protocol
  •  go-up   go-down


6. Chalastras T, Elefteriadou A, Giotakis J, Soulandikas K, Korres S, Ferekidis E, Kandiloros D: Non-Hodgkin's lymphoma of nasal cavity and paranasal sinuses. A clinicopathological and immunohistochemical study. Acta Otorhinolaryngol Ital; 2007 Feb;27(1):6-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma of nasal cavity and paranasal sinuses. A clinicopathological and immunohistochemical study.
  • Aim of this study was to investigate the clinical characteristics, management and prognosis of non-Hodgkin lymphomas of the nasal cavity and paranasal sinuses.
  • Patients' data collected were age, sex, presenting signs and symptoms, histology, treatment, complications, and outcome.
  • Also available were computerised tomography findings, and paraffin-embedded tissue bocks.
  • Using immunocytochemistry on paraffin-embedded tissue sections, the predominance of large B-cell subtype was detected.
  • Treatment administered: only radiotherapy (stage IEA) or in combination with chemotherapy (IIE-IVE).
  • Early diagnosis, based mainly on tissue biopsy and computerised tomography, is essential in the management of non-Hodgkin lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / immunology. Lymphoma, Non-Hodgkin / radiography. Paranasal Sinus Neoplasms / immunology. Paranasal Sinus Neoplasms / radiography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Combined Modality Therapy. Female. Humans. Immunohistochemistry. Male. Middle Aged. Nasal Cavity. Neoplasm Staging. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 2000 Aug;124(8):1213-6 [10923086.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1999 Apr;108(4):411-9 [10214792.001]
  • [Cites] Auris Nasus Larynx. 2001 Jan;28(1):55-60 [11137364.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 Mar;97(3):328-31 [15024355.001]
  • [Cites] Cancer. 1982 May 15;49(10):2112-35 [6896167.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):768-76 [4016670.001]
  • [Cites] Pathology. 1986 Oct;18(4):419-25 [3493470.001]
  • [Cites] Lancet. 1988 Feb 6;1(8580):292-3 [2893097.001]
  • [Cites] Hum Pathol. 1989 Jul;20(7):636-42 [2661407.001]
  • [Cites] Am J Surg Pathol. 1991 Mar;15(3):268-79 [1996731.001]
  • [Cites] CA Cancer J Clin. 1993 Jan-Feb;43(1):7-26 [8422609.001]
  • [Cites] Blood. 1993 May 15;81(10):2688-95 [8387835.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1994 Apr;103(4 Pt 1):294-300 [8154771.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Cancer. 1995 Mar 15;75(6):1281-91 [7882278.001]
  • [Cites] Cancer. 1997 Aug 1;80(3):477-88 [9241082.001]
  • [Cites] Laryngoscope. 2000 Sep;110(9):1489-92 [10983948.001]
  • (PMID = 17601204.001).
  • [ISSN] 0392-100X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2640014
  •  go-up   go-down


7. Airoldi M, Garzaro M, Valente G, Mamo C, Bena A, Giordano C, Pecorari G, Gabriele P, Gabriele AM, Beatrice F: Clinical and biological prognostic factors in 179 cases with sinonasal carcinoma treated in the Italian Piedmont region. Oncology; 2009;76(4):262-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and biological prognostic factors in 179 cases with sinonasal carcinoma treated in the Italian Piedmont region.
  • OBJECTIVES: In spite of aggressive surgery and high-dose radiotherapy, the long-term survival of patients with sinonasal cancer remains disappointing.
  • Patients treated with surgery with or without radiotherapy had better survival (p < 0.01), while chemotherapy had a marginally favorable effect (p = 0.09).
  • The type of surgery and radiotherapy dose had no impact on survival; in contrast, there was a strong association between Ki-67 expression and microvessel density and overall survival (p < 0.05 and p = 0.039, respectively), while VEGF-C was a prognostic factor in SCC patients only (p < 0.05).
  • CONCLUSIONS: In sinonasal cancer, tumor stage and histology have a clear impact on survival; surgery with or without radiotherapy represents the main choice of treatment for such tumors.
  • The proliferative index and angiogenesis show a major role in the natural history of this cancer.
  • [MeSH-major] Paranasal Sinus Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD31 / analysis. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Vascular Endothelial Growth Factor C / analysis

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19258726.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Vascular Endothelial Growth Factor C
  •  go-up   go-down


8. Yao M, Dornfeld KJ, Buatti JM, Skwarchuk M, Tan H, Nguyen T, Wacha J, Bayouth JE, Funk GF, Smith RB, Graham SM, Chang K, Hoffman HT: Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma--the University of Iowa experience. Int J Radiat Oncol Biol Phys; 2005 Oct 1;63(2):410-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma--the University of Iowa experience.
  • PURPOSE: To review the University of Iowa experience with intensity-modulated radiotherapy (IMRT) in the treatment of head-and-neck squamous cell carcinoma.
  • METHODS AND MATERIALS: From October 1999 to April 2004, 151 patients with head-and-neck squamous cell carcinoma were treated with IMRT for curative intent.
  • One patient was lost to follow-up 2 months after treatment and therefore excluded from analysis.
  • Of the remaining 150 patients, 99 were treated with definitive IMRT, and 51 received postoperative IMRT.
  • Sites included were nasopharynx, 5; oropharynx, 56; larynx, 33; oral cavity, 29; hypopharynx, 8; nasal cavity/paranasal sinus, 8; and unknown primary, 11.
  • None of the patients treated with postoperative IMRT received chemotherapy.
  • Of 99 patients who had definitive IMRT, 68 patients received concurrent cisplatin-based chemotherapy.
  • One patient received induction cisplatin-based chemotherapy, but no concurrent chemotherapy was given.
  • The prescribed doses to CTV1, CTV2, and CTV3 in the definitive cohort were 70-74 Gy, 60 Gy, and 54 Gy, respectively.
  • For high-risk postoperative IMRT, the prescribed doses to CTV1, CTV2, and CTV3 were 64-66 Gy, 60 Gy, and 54 Gy, respectively.
  • For intermediate-risk postoperative IMRT, the prescribed doses to CTV1, CTV2, and CTV3 were 60 Gy, 60 Gy, and 54 Gy.
  • The median time from treatment completion to local-regional recurrence was 4.7 months (range, 1.8 to 15.6 months).
  • Only one marginal failure was noted in a patient who had extensive tonsil cancer with tumor extension into the orbit and cavernous sinus.
  • Patients with oropharyngeal cancer did significantly better than patients with oral cavity and laryngeal cancer, with a 2-year local-regional control rate of 98%, compared with 78% for oral cavity cancer and 85% for laryngeal cancer (p = 0.005).
  • There was no significant difference in local-regional control for patients who received postoperative radiation or definitive radiation (p = 0.339) and for patients who had chemotherapy or not (p = 0.402).
  • Neither T stage nor N stage had a significant effect on local-regional control (p = 0.722 and 0.712, respectively).
  • CONCLUSIONS: Our results have confirmed the effectiveness of IMRT in head-and-neck cancer.
  • More studies are necessary to further improve the outcomes of laryngeal cancer as well as oral cavity cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / radiotherapy. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy. Female. Humans. Iowa. Male. Middle Aged. Radiotherapy Dosage. Radiotherapy Planning, Computer-Assisted. Retrospective Studies. Survival Analysis. Tomography, X-Ray Computed. Treatment Failure. Universities

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16168834.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


9. Kim JG, Sohn SK, Kim DH, Baek JH, Jeon SB, Chae YS, Lee KB, Park JS, Sohn JH, Kim JC, Park IK: Phase II study of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck. Br J Cancer; 2005 Nov 14;93(10):1117-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck.
  • We aimed to evaluate the efficacy and safety of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
  • In total, 37 patients with stage III or IV SCCHN were enrolled on the study.
  • The chemotherapy consisted of two cycles of intravenous cisplatin of 80 mg m(-2) on day 1 and oral capecitabine 825 mg m(-2) twice daily from day 1 to day 14 at 3-week intervals.
  • The radiotherapy (1.8-2.0 Gy 1 fraction day(-1) to a total dose of 70-70.2 Gy) was delivered to the primary tumour site and neck.
  • The primary tumour sites were as follows: oral cavity (n=6), oropharynx (n=11), hypopharynx (n=8), larynx (n=3), nasopharynx (n=6), and paranasal sinus (n=3).
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Cisplatin / therapeutic use. Deoxycytidine / analogs & derivatives. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Capecitabine. Disease Progression. Drug Therapy, Combination. Female. Fluorouracil / analogs & derivatives. Humans. Male. Middle Aged. Neoplasm Staging. Survival Rate

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1652-61 [10764425.001]
  • [Cites] J Clin Oncol. 2001 Nov 1;19(21):4097-106 [11689577.001]
  • [Cites] Cancer. 2002 Oct 1;95(7):1472-81 [12237916.001]
  • [Cites] Ann Oncol. 2002 Dec;13(12):1893-8 [12453857.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):92-8 [12506176.001]
  • [Cites] Ann Oncol. 2003 Jul;14(7):1115-20 [12853355.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3098-104 [12915600.001]
  • [Cites] Ann Oncol. 2003 Oct;14(10):1578-86 [14504061.001]
  • [Cites] Br J Cancer. 2004 Jan 26;90(2):348-52 [14735175.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] N Engl J Med. 1993 Jan 21;328(3):184-94 [8417385.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2648-53 [7989940.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1318-24 [9552032.001]
  • [Cites] Biochem Pharmacol. 1998 Apr 1;55(7):1091-7 [9605432.001]
  • [Cites] N Engl J Med. 1998 Jun 18;338(25):1798-804 [9632446.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1274-81 [9849491.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):485-93 [10080589.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1350-7 [15684318.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):346-53 [15913913.001]
  • [Cites] J Clin Oncol. 2001 Apr 1;19(7):1961-9 [11283128.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10):2948-53 [10537364.001]
  • [Cites] J Natl Cancer Inst. 1999 Dec 15;91(24):2081-6 [10601378.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):876-83 [10679658.001]
  • [Cites] Cancer Chemother Pharmacol. 2000;45(4):291-7 [10755317.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2282-92 [11304782.001]
  • (PMID = 16251869.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2361495
  •  go-up   go-down


10. Daele JJ, Vander Poorten V, Rombaux P, Hamoir M: Cancer of the nasal vestibule, nasal cavity and paranasal sinuses. B-ENT; 2005;Suppl 1:87-94; quiz 95-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer of the nasal vestibule, nasal cavity and paranasal sinuses.
  • The usual clinical presentation of sinonasal tumours includes symptoms that are indistinguishable from inflammatory sinus disease, namely nasal airway obstruction, pain, and epistaxis.
  • Computed tomography is the most reliable and informative imaging tool for evaluating the cancers of the paranasal sinuses.
  • Magnetic resonance imaging is essential for tumour mapping because of the excellent tissue characterisation and the possibility of differentiating between neoplasms and retained secretions.
  • A wide variety of histologies may be encountered, although squamous cell carcinoma (SCCA) is the most common.
  • The response of sinonasal tract tumours to radiation therapy varies with the stage and histology of the tumour.
  • Management of these tumours requires a multimodal approach, involving surgery, radiation therapy and, increasingly in recent years, chemotherapy.
  • [MeSH-major] Nasal Cavity / pathology. Nose Neoplasms / diagnosis. Paranasal Sinus Neoplasms / diagnosis
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Magnetic Resonance Imaging. Neoplasm Invasiveness. Radiotherapy, Adjuvant. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16363270.001).
  • [ISSN] 1781-782X
  • [Journal-full-title] B-ENT
  • [ISO-abbreviation] B-ENT
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Belgium
  • [Number-of-references] 49
  •  go-up   go-down


11. Boussen H, Sethom A, Beddouihech N, Touati S, Gamoudi A, Gritli S, El May A, Ferjaoui M, Benna F, Ladgham A: [Primary sino-nasal lymphomas. Apropos of 25 cases]. Cancer Radiother; 2001 Apr;5(2):150-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To report on the epidemiological and therapeutic features of a series of Tunisian patients treated for primitive sinonasal lymphoma.
  • Treatment is based on radiotherapy with or without chemotherapy (mainly with the CHOP protocol).
  • High-grade lymphomas represented 60% of the cases, and 60% of the patients were stage IE.
  • All stage IEs have been treated by exclusive radiotherapy while more advanced stages received combined chemo- and radiotherapy (eight patients).
  • The five-year actuarial survival rate was 69% for the whole population, with a better prognosis for localized stage and low-grade lymphomas.
  • DISCUSSION: Radiotherapy remains a standard treatment for sinonasal lymphomas, permitting us to cure localized stages.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology. Nose Neoplasms / epidemiology. Paranasal Sinus Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Airway Obstruction / etiology. Chemotherapy, Adjuvant. Combined Modality Therapy. Epistaxis / etiology. Female. Humans. Life Tables. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis. Survival Rate. Treatment Outcome. Tunisia / epidemiology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11355579.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 15
  •  go-up   go-down


12. Uchida D, Shirato H, Onimaru R, Endou H, Aoyama H, Tsuchiya K, Nishioka T, Homma A, Furuta Y, Fukuda S, Miyasaka K: Long-term results of ethmoid squamous cell or undifferentiated carcinoma treated with radiotherapy with or without surgery. Cancer J; 2005 Mar-Apr;11(2):152-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of ethmoid squamous cell or undifferentiated carcinoma treated with radiotherapy with or without surgery.
  • PURPOSE: Ethmoidal malignant tumors, for which intensity-modulated radiotherapy is expected to improve outcome, consist of heterogeneous pathological types.
  • Reports about their outcome are influenced by the inclusion of favorable histology, such as adenocarcinoma and adenoid cystic carcinoma.
  • We investigated the long-term treatment outcome of squamous cell carcinoma and undifferentiated carcinoma of the ethmoid sinus.
  • One (4%) had stage T2 disease, seven (28%) had stage T3, three (12%) had stage T4a, and 14 (56%) had stage T4b.
  • Radiation dose varied from 50.4 Gy in 16 fractions (50.4 Gy/16 Fr) to 65 Gy in 26 fractions with or without stereotactic boost irradiation.
  • Eleven patients received chemotherapy consisting mainly of platinum-based compounds.
  • CONCLUSION: Ethmoid squamous cell carcinoma or undifferentiated carcinoma was diagnosed at advanced T stages and was treated with radiotherapy; these patients had a poorer outcome than patients with adenocarcinoma or adenoid cystic carcinoma.
  • Prospective trials using advanced technology should be carefully compared with historical controls because pathological types can considerably influence the treatment results.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Ethmoid Sinus / pathology. Paranasal Sinus Neoplasms / radiotherapy. Treatment Outcome
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Radiotherapy Dosage. Survival Analysis. Time Factors

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15969991.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Lin CY, Chen HH, Chen HH, Fang SY, Tsai ST: Ethmoid sinus cancer: results of treatment with surgery and combined therapy. Acta Otolaryngol; 2004 Dec;124(10):1220-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ethmoid sinus cancer: results of treatment with surgery and combined therapy.
  • OBJECTIVE: Ethmoid sinus cancer is a rare paranasal sinus malignancy.
  • Its characteristics include a low incidence rate, a great variety of histopathological types and multiple treatment modalities.
  • The aim of this study was to examine the outcome of a population of Asian patients with advanced ethmoid sinus cancers that had been treated with surgery plus combined therapy.
  • MATERIAL AND METHODS: Between January 1989 and December 2002 inclusive, 19 newly diagnosed patients with ethmoid sinus cancers who had undergone surgical intervention were enrolled, T4 being the principal carcinoma stage (68.4%).
  • All participating cases proved to be node-negative and no evidence of any distant metastasis was detected at the time of diagnosis.
  • The major treatment modality was surgery plus postoperative radiotherapy.
  • All but 2 of the 13 patients with T4 cancer underwent craniofacial resection with pericranial flap reconstruction.
  • RESULTS: The estimated overall and disease-free survival rates 3 years post-treatment were 49.4% and 26.3%, respectively.
  • A total of 5/15 T3-T4 patients (33%) developed a neck metastasis, 3 of whom also suffered a distant metastasis.
  • CONCLUSIONS: Ethmoid sinus cancer typically demonstrates a propensity for late diagnosis and poor prognosis.
  • This study confirms that craniofacial resection plus combined associated therapy is the optimal approach for the effective management of extensive ethmoid sinus tumors and is associated with an acceptable morbidity rate.
  • More aggressive disease management featuring prophylactic concurrent chemoradiotherapy including neck or elective neck dissection plus chemotherapy should be considered for T3-T4 patients as opposed to T1-T2 patients.
  • [MeSH-major] Carcinoma / therapy. Ethmoid Sinus. Paranasal Sinus Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Survival Rate

  • Genetic Alliance. consumer health - Sinus cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15768822.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


14. Guntinas-Lichius O, Wendt T, Buentzel J, Esser D, Lochner P, Mueller A, Schultze-Mosgau S, Altendorf-Hofmann A: Head and neck cancer in Germany: a site-specific analysis of survival of the Thuringian cancer registration database. J Cancer Res Clin Oncol; 2010 Jan;136(1):55-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Head and neck cancer in Germany: a site-specific analysis of survival of the Thuringian cancer registration database.
  • OBJECTIVE: To describe epidemiology and prognosis of head and neck cancer in Germany.
  • METHODS: We analyzed the Thuringian cancer registry database from 1996 to 2005.
  • 3,821 cases with primary head and neck cancer were evaluated for patient's characteristics, tumor stage, incidence, treatment, and trends in overall survival.
  • RESULTS: During the period 1996-2005, the incidence of oropharynx, hypopharynx, larynx, and salivary gland cancer increased significantly for males, and of oral cavity and hypopharynx cancer for females.
  • There was a significant trend using more multimodal therapy combining surgery, radiotherapy, and chemotherapy, and to use less radiotherapy as a single modality.
  • The median follow-up time of patients alive was 42 months.
  • The site-specific 5-year OS for lip, oral cavity, nasopharynx, oropharynx, hypopharynx, larynx, salivary gland, and nose/paranasal sinus cancer was 75.7, 42.6, 43.5, 45.9, 27.2, 57.3, 61.0, and 34.9%, respectively.
  • The multivariate analysis showed that male gender, age ≥ 60 years, therapy without surgery, higher T classification, N classification, and M classification were independent significant negative risk factors for OS (p < 0.0001).
  • Cancer of the oral cavity and of the hypopharynx had a significant lower OS than lip cancer (p = 0.012 and p = 0.044, respectively).
  • CONCLUSIONS: Many subsites of head and neck cancer have changing incidence.
  • Although treatment strategies have changed, outcome has not improved significantly from 1995 to 2006.
  • [MeSH-major] Databases, Factual / statistics & numerical data. Head and Neck Neoplasms / epidemiology. Head and Neck Neoplasms / therapy. Registries / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Germany / epidemiology. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Survival Analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMC Public Health. 2006 Jun 06;6:146 [16756650.001]
  • [Cites] N Engl J Med. 2008 Sep 11;359(11):1143-54 [18784104.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2201-7 [9827726.001]
  • [Cites] Head Neck. 2005 Oct;27(10):843-50 [16161069.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Otolaryngol Head Neck Surg. 2006 Sep;135(3):451-7 [16949981.001]
  • [Cites] Lancet Oncol. 2007 Sep;8(9):784-96 [17714993.001]
  • [Cites] Cancer. 2008 Nov 15;113(10 Suppl):2901-9 [18980273.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1998 Sep;124(9):951-62 [9738803.001]
  • [Cites] Z Gerontol Geriatr. 2005 Feb;38(1):47-59 [15756487.001]
  • [Cites] Mayo Clin Proc. 2008 Apr;83(4):489-501 [18380996.001]
  • [Cites] Semin Oncol. 2008 Jun;35(3):221-8 [18544437.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):581-92 [17287242.001]
  • [Cites] Eur Addict Res. 2003 Oct;9(4):147-56 [12970583.001]
  • [Cites] Laryngorhinootologie. 2002 Jul;81(7):499-508 [12173061.001]
  • [Cites] Int J Cancer. 2005 May 1;114(5):806-16 [15609302.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 5:v61-118 [14684501.001]
  • (PMID = 19568769.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


15. Guntinas-Lichius O, Kreppel MP, Stuetzer H, Semrau R, Eckel HE, Mueller RP: Single modality and multimodality treatment of nasal and paranasal sinuses cancer: a single institution experience of 229 patients. Eur J Surg Oncol; 2007 Mar;33(2):222-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single modality and multimodality treatment of nasal and paranasal sinuses cancer: a single institution experience of 229 patients.
  • AIMS: To assess the single and multimodal treatment results and prognostic factors for sinonasal carcinoma.
  • METHODS: Overall survival (OS), disease-specific survival (DSS), local control (LC), and disease-free survival (DFS) in 229 patients with sinonasal carcinoma treated from 1967 to 2003 were calculated.
  • RESULTS: 32% of the patients were operated only, 47% underwent multimodal therapy, and 20% were treated without operation.
  • Prognostic for DSS were M status (p<0.001), UICC stage (p<0.001), T classification (p=0.001), N status (p=0.002), intracranial tumor infiltration (p=0.008), infiltration of the pterygopalatine fossa (p=0.02), infiltration of the skull base (p=0.021), infiltration of the orbita (p=0.041), and the type of therapy (p<0.001): The 5-year DSS rate was 63% for patients operated only, 56% for all operated patients, 46% for patients undergoing surgery and radiotherapy, but only 21% for patients treated with radiotherapy+/-chemotherapy.
  • Multivariate analysis revealed that T classification (p=0.042), N classification (p=0.035), M classification (p=0.007), UICC stage (p=0.038), and type of therapy (p=0.038) were independent prognostic factors for DSS.
  • CONCLUSIONS: Radical surgery is recommended for stage I/II sinonasal carcinomas.
  • Stage III/IV carcinomas still have a poor prognosis, but multimodal treatment seems to favor the outcome.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Nose Neoplasms / therapy. Otorhinolaryngologic Surgical Procedures / methods. Paranasal Sinus Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Germany / epidemiology. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate / trends. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17127030.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


16. Khademi B, Moradi A, Hoseini S, Mohammadianpanah M: Malignant neoplasms of the sinonasal tract: report of 71 patients and literature review and analysis. Oral Maxillofac Surg; 2009 Dec;13(4):191-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The present study aimed to report the characteristics, prognostic factors, and treatment outcomes of 71 cases of malignant neoplasms of the sinonasal tract and literature review and analysis of major report series.
  • Thirty-four patients were treated with surgery followed by a combination of chemotherapy and radiotherapy, 15 with surgery alone, 14 with combined radiotherapy and chemotherapy, six with radiotherapy alone, and two with surgery followed by radiotherapy.
  • The primary sites included were paranasal sinuses in 51 and nasal cavity in 20.
  • There were one case of stage I, 20 of stage II, 27 of stage III, and 23 of stage IV.
  • Local recurrence was the most frequent treatment failure.
  • On univariate analysis, cervical lymph nodes involvement, primary tumor size, histologic type, response to therapy, and stage of disease were independent prognostic factors for overall survival.
  • Local recurrence was the dominant treatment failure in nearly all series.
  • CONCLUSIONS: In this review and by analyzing the large data collection of recent major reported series, we found that malignant neoplasms of the sinonasal tract tend to present at locally advanced stage, with a high frequency of local failure and a moderate to poor outcome.
  • More effective local treatment for improving the local control and overall survival is needed.
  • [MeSH-major] Carcinoma / pathology. Nose Neoplasms / pathology. Paranasal Sinus Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Cisplatin / therapeutic use. Cobalt Radioisotopes / therapeutic use. Disease-Free Survival. Female. Fluorouracil / therapeutic use. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Proportional Hazards Models. Radiography. Young Adult

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Med Assoc. 2007 Dec;99(12):1407-10 [18229778.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Aug;130(8):948-55 [15313865.001]
  • [Cites] Head Neck. 1998 Mar;20(2):97-105 [9484939.001]
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • [Cites] Am J Rhinol. 1999 Mar-Apr;13(2):117-23 [10219440.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1042-50 [17570610.001]
  • [Cites] Acta Oncol. 1997;36(1):45-50 [9090965.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):141-7 [17459609.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 1992 Mar;14(2):135-7 [1618083.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Mar 1;67(3):691-702 [17161557.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2005 Feb;27(2):117-21 [15946555.001]
  • [Cites] J Laryngol Otol. 1980 Mar;94(3):301-9 [7373133.001]
  • [Cites] Otolaryngol Pol. 2008;62(4):436-41 [18837219.001]
  • [Cites] HNO. 2005 Nov;53(11):957-65 [15883842.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2009 Feb;135(2):173-9 [19221246.001]
  • [Cites] Wiad Lek. 2006;59(11-12):797-800 [17427494.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1991 Mar;3(2):84-9 [2031888.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 Apr;122(4):499-508 [10740168.001]
  • [Cites] Tumori. 1986 Dec 31;72(6):589-95 [3810867.001]
  • [Cites] Head Neck. 2000 Dec;22(8):772-80 [11084637.001]
  • [Cites] Acta Oncol. 1997;36(1):27-31 [9090960.001]
  • [Cites] Laryngoscope. 2009 May;119(5):899-906 [19358246.001]
  • [Cites] Radiol Med. 1994 Sep;88(3):291-4 [7938737.001]
  • [Cites] J Laryngol Otol. 2007 Jan;121(1):49-56 [16995961.001]
  • [Cites] CA Cancer J Clin. 2005 Jul-Aug;55(4):242-58; quiz 261-2, 264 [16020425.001]
  • [Cites] Laryngorhinootologie. 1991 Mar;70(3):138-41 [2036148.001]
  • [Cites] Acta Radiol Oncol. 1984;23(2-3):181-7 [6331089.001]
  • [Cites] Zhonghua Er Bi Yan Hou Ke Za Zhi. 2000 Jun;35(3):168-71 [12768768.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Apr 1;73(5):1343-51 [18963535.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3012-29 [11753979.001]
  • [Cites] Otolaryngol Pol. 2000;54(1):13-5 [10822961.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):424-32 [18755554.001]
  • [Cites] Ann Otolaryngol Chir Cervicofac. 2006 Jun;123(3):115-9 [16840900.001]
  • [Cites] Jpn J Clin Oncol. 1995 Oct;25(5):188-94 [7474406.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Sep;128(9):1079-83 [12220216.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):27-35 [10924968.001]
  • [Cites] Curr Oncol Rep. 2007 Mar;9(2):147-51 [17288882.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):51-8 [15093898.001]
  • [Cites] Acta Otorrinolaringol Esp. 2006 Oct;57(8):359-63 [17117693.001]
  • [Cites] Cancer. 2003 Nov 15;98(10):2214-23 [14601092.001]
  • [Cites] Expert Rev Anticancer Ther. 2004 Jun;4(3):411-24 [15161440.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2008 Feb;134(2):170-7 [18283160.001]
  • [Cites] Head Neck. 2004 Apr;26(4):322-30 [15054735.001]
  • [Cites] Otolaryngol Pol. 2006;60(5):729-36 [17263246.001]
  • [Cites] Otolaryngol Head Neck Surg. 2004 Dec;131(6):973-6 [15577800.001]
  • [Cites] Head Neck. 2002 Sep;24(9):821-9 [12211046.001]
  • [Cites] Ai Zheng. 2004 Nov;23(11 Suppl):1542-5 [15566676.001]
  • [Cites] Am J Otolaryngol. 1995 Mar-Apr;16(2):109-14 [7793504.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):719-30 [17543999.001]
  • [Cites] J Int Med Res. 2009 Jan-Feb;37(1):189-97 [19215690.001]
  • [Cites] Head Neck. 1995 Mar-Apr;17(2):114-8 [7558807.001]
  • [Cites] Am J Surg. 1989 Oct;158(4):328-32 [2802037.001]
  • [Cites] Rhinology. 1998 Mar;36(1):12-4 [9569435.001]
  • [Cites] Eur J Surg Oncol. 2005 Dec;31(10):1206-12 [15923101.001]
  • [Cites] J Otolaryngol. 2005 Dec;34(6):379-83 [16343397.001]
  • [Cites] Eur J Surg Oncol. 2007 Mar;33(2):222-8 [17127030.001]
  • [Cites] Acta Oncol. 2001;40(1):19-23 [11321654.001]
  • [Cites] Otolaryngol Pol. 2008;62(1):37-43 [18637419.001]
  • [Cites] Ir J Med Sci. 1995 Apr-Jun;164(2):139-41 [7607840.001]
  • [Cites] Head Neck. 2006 Oct;28(10):867-73 [16823871.001]
  • [Cites] Head Neck. 2005 Jul;27(7):575-84 [15825201.001]
  • [Cites] Otolaryngol Pol. 2007;61(4):572-5 [18260254.001]
  • (PMID = 19795137.001).
  • [ISSN] 1865-1569
  • [Journal-full-title] Oral and maxillofacial surgery
  • [ISO-abbreviation] Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cobalt Radioisotopes; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Number-of-references] 62
  •  go-up   go-down


17. Laskin JJ, Savage KJ, Voss N, Gascoyne RD, Connors JM: Primary paranasal sinus lymphoma: natural history and improved outcome with central nervous system chemoprophylaxis. Leuk Lymphoma; 2005 Dec;46(12):1721-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary paranasal sinus lymphoma: natural history and improved outcome with central nervous system chemoprophylaxis.
  • Non-Hodgkin's lymphoma of the paranasal sinus is an uncommon presentation of extranodal lymphoma.
  • Its natural history, treatment and prognosis have been infrequently characterized in the medical literature; however, a tendency to involve the central nervous system (CNS) has been noted.
  • In British Columbia (population 4 million), a central database for lymphomas has allowed us to accurately track cases of paranasal sinus lymphoma diagnosed since 1980.
  • A retrospective review was performed on the 44 patients who presented with primary paranasal sinus lymphoma (stage I or II) between 1980 and 1999.
  • Complete diagnostic and follow-up data including stage, treatment, response rates, sites of relapse and survival data were available for all patients.
  • The types of lymphoma found were: diffuse large B cell (including immunoblastic), n = 37 (84%); T/NK nasal type, n = 3 (8%); peripheral T cell, not otherwise classified, n = 2 (4%); and others, n = 2 (4%).
  • Beginning in May 1985, intrathecal chemotherapy was added to our standard treatment plan of multi-agent chemotherapy and local irradiation.
  • Before 1985, 2 of 5 patients developed leptomeningeal metastasis.
  • Following the institution of intrathecal chemotherapy, only 8% (3 of 39) of patients have developed CNS disease.
  • Primary paranasal sinus lymphoma is an uncommon presentation of lymphoma that carries the potential risk of spreading to the leptomeninges.
  • Treatment with combined modality chemotherapy and irradiation can cure many patients and the addition of intrathecal chemotherapy may reduce the risk of CNS relapse.
  • [MeSH-major] Chemoprevention. Lymphoma, Non-Hodgkin / physiopathology. Paranasal Sinus Neoplasms / physiopathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / prevention & control. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Analysis. Survivors. Treatment Outcome

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16263574.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


18. Peng RQ, Wu GH, Chen WK, Ding Y, Ma J, Zhang NH, Su YS, Zhang XS: [Clinical characteristics and prognosis of primary nasal mucosal melanoma--a report of 44 cases]. Ai Zheng; 2006 Oct;25(10):1284-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & OBJECTIVE: Primary mucosal malignant melanoma of the nasal cavity, paranasal sinuses, and nasopharynx is rare and current research data of this disease are mainly from western populations.
  • 2005, 66 patients with primary nasal mucosal melanoma were treated in Cancer Center of Sun Yat-sen University, China.
  • Demographics and baseline characteristics, treatments, recurrence, metastasis, and survival were documented in hospital records.
  • RESULTS: Among 44 evaluable cases, 37 were originated from the nasal cavity, 5 from the paranasal sinuses, and 2 from the nasopharynx.
  • Of the 31 patients received operation-dominated treatment, 8 received adjuvant radiotherapy, 13 received adjuvant chemotherapy, and 6 received adjuvant non-specific immunotherapy.
  • The median time of follow-up was 29 months.
  • The median survival time was 24 months and the 5-year survival time was 25%.
  • Clinical stage affected prognosis, whereas age, gender, site, primary tumor mass, and adjuvant therapy were not correlated to survival status.
  • Clinical stage affects the prognosis.
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Nasal Cavity. Neoplasm Staging. Paranasal Sinus Neoplasms / pathology. Paranasal Sinus Neoplasms / surgery. Paranasal Sinus Neoplasms / therapy. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17059777.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


19. Lajtman Z, Manestar D: A comparison of surgery and radiotherapy in the management of advanced pyriform fossa carcinoma. Clin Otolaryngol Allied Sci; 2001 Feb;26(1):59-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparison of surgery and radiotherapy in the management of advanced pyriform fossa carcinoma.
  • This retrospective study analyses the outcome of treatment of 61 patients with advanced carcinoma of the pyriform fossa.
  • Thirty-two patients (group 1) underwent surgery and postoperative radiotherapy and 29 patients (group 2) had induction chemotherapy followed by radiotherapy.
  • The local recurrence-free survival at 5 years from the completion of therapy for group 1 was 54%, compared to 61% for group 2.
  • Non-surgical therapy for advanced stage pyriform fossa cancer provides survival comparable with that achieved with the standard approach of surgery and postoperative radiotherapy.
  • But, however, despite the therapy, the outcome is poor.
  • [MeSH-major] Carcinoma / radiotherapy. Carcinoma / surgery. Paranasal Sinus Neoplasms / radiotherapy. Paranasal Sinus Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11298170.001).
  • [ISSN] 0307-7772
  • [Journal-full-title] Clinical otolaryngology and allied sciences
  • [ISO-abbreviation] Clin Otolaryngol Allied Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


20. Su ZY, Zhang DS, Zhu MQ, Shi YX, Jiang WQ: [Primary non-Hodgkin's lymphoma of the paranasal sinuses: a report of 14 cases]. Ai Zheng; 2007 Aug;26(8):919-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary non-Hodgkin's lymphoma of the paranasal sinuses: a report of 14 cases].
  • BACKGROUND & OBJECTIVE: Primary paranasal sinus lymphoma (PPSL) is a rare presentation of extranodal non-Hodgkin's lymphoma with a natural history distinct from other lymphomas.
  • This study was to evaluate the clinical and pathologic characteristics, treatment outcomes and prognosis of PPSL.
  • METHODS: The records of 14 PPSL patients, treated at Cancer Center of Sun Yat-sen University from 1994 to 2006, were analyzed.
  • RESULTS: The primary involvement sites included the maxillary sinus (11 cases), ethmoid sinus (2 cases), and sphenoid sinus (1 case).
  • All patients were at stage I-II (Ann Arbor system).
  • According to the AJCC TNM staging system, most patients had advanced T3-T4 disease.
  • The most common type was diffuse large B-cell PPSL (6 cases, 42.9%).
  • All patients received chemotherapy and 6 received radiotherapy after chemotherapy.
  • Diffuse large B-cell lymphoma is the most common histologic type and the maxillary sinus is the most common original site of PPSL.
  • A combined-modality approach with systemic chemotherapy and local-regional radiation is recommended for PPSL patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Paranasal Sinus Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Follow-Up Studies. Humans. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell / radiotherapy. Lymphoma, T-Cell / surgery. Maxillary Sinus / surgery. Middle Aged. Neoplasm Staging. Paranasal Sinuses / pathology. Prednisone / therapeutic use. Remission Induction. Survival Rate. Vincristine / therapeutic use. Young Adult

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17697560.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


21. Woo JS, Kim JM, Lee SH, Chae SW, Hwang SJ, Lee HM: Clinical analysis of extranodal non-Hodgkin's lymphoma in the sinonasal tract. Eur Arch Otorhinolaryngol; 2004 Apr;261(4):197-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigated the clinical analysis of non-Hodgkin's lymphoma (NHL) of the sinonasal tract, including the survival rate and treatment outcome.
  • Even though higher mortality rates were observed in patients receiving chemotherapy alone than in those receiving chemotherapy and radiation therapy in the advanced stage, the combination treatment of chemotherapy and radiation therapy failed to demonstrate a significantly higher survival rate.
  • [MeSH-major] Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / therapy. Paranasal Sinus Neoplasms / mortality. Paranasal Sinus Neoplasms / therapy. Paranasal Sinuses / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Biopsy, Needle. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Probability. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Risk Factors. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1987 Jun;11(6):418-29 [3496014.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] Ann Oncol. 2001 Mar;12(3):349-52 [11332147.001]
  • [Cites] Hum Pathol. 1997 Jul;28(7):834-9 [9224753.001]
  • [Cites] Am J Clin Pathol. 1999 Jan;111(1 Suppl 1):S46-55 [9894469.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):153-60 [10924985.001]
  • [Cites] Int J Cancer. 1984 Aug 15;34(2):143-8 [6381328.001]
  • [Cites] Acta Oncol. 1997;36(3):307-11 [9208902.001]
  • [Cites] Auris Nasus Larynx. 2001 Jan;28(1):55-60 [11137364.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):161-8 [10924986.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Yonsei Med J. 2002 Apr;43(2):175-82 [11971211.001]
  • [Cites] Hematol Oncol. 2001 Dec;19(4):129-50 [11754390.001]
  • [Cites] Am J Surg Pathol. 1996 Jan;20(1):103-11 [8540601.001]
  • [Cites] Cancer. 1990 Nov 15;66(10):2205-9 [2224776.001]
  • [Cites] Radiology. 1997 Aug;204(2):467-70 [9240537.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1989;414(5):399-405 [2499096.001]
  • [Cites] N Engl J Med. 1998 Jul 2;339(1):21-6 [9647875.001]
  • [Cites] Hum Pathol. 1987 Dec;18(12):1257-62 [3500108.001]
  • [Cites] Cancer. 1997 Aug 1;80(3):477-88 [9241082.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):643-51 [11849785.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Dec 1;51(5):1228-33 [11728681.001]
  • [Cites] Blood. 1993 May 15;81(10):2688-95 [8387835.001]
  • [Cites] Cancer. 1998 Aug 15;83(4):806-12 [9708949.001]
  • [Cites] Laryngoscope. 2000 Sep;110(9):1489-92 [10983948.001]
  • [Cites] Hum Pathol. 1994 Jul;25(7):659-65 [8026825.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1994 Nov;103(11):911-4 [7979008.001]
  • [Cites] Br J Haematol. 1997 Jun;97(4):821-9 [9217183.001]
  • [Cites] Histopathology. 1994 Dec;25(6):517-36 [7698729.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):70-7 [9440725.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1990 Jan;116(1):69-73 [2294944.001]
  • (PMID = 12898138.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


22. Cimino L, Chan CC, Shen D, Masini L, Ilariucci F, Masetti M, Asioli S, Sartori A, Cappuccini L: Ocular involvement in nasal natural killer T-cell lymphoma. Int Ophthalmol; 2009 Aug;29(4):275-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To describe the clinical, morphologic, and immunohistochemical features of a case of paranasal natural killer/T-cell lymphoma (NKTL) with ocular involvement.
  • In July she underwent a nasal computed tomography (CT) scan and multiple biopsies of the granulomatous tissue in the nasal fossae.
  • The diagnosis was NK/T non-Hodgkin's lymphoma nasal type, stage IV A.
  • In October she started chemotherapy cycles.
  • RESULTS: A diagnosis of T-lymphoma cells in the vitreous was made; the tumor was most likely originating from her paranasal NKTL.
  • CONCLUSIONS: Nasal and paranasal sinus lymphomas are rare, but aggressive diseases with a tendency to invade tissues and spread to CNS, including the eye.
  • Ocular manifestations prior to systemic ones may be useful to monitor the response to therapy.
  • [MeSH-major] Eye / pathology. Lymphoma, T-Cell / pathology. Natural Killer T-Cells. Paranasal Sinus Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Fatal Outcome. Female. Fundus Oculi. Humans. Middle Aged. Neoplasm Invasiveness. Prednisone / therapeutic use. Recurrence. Uveitis / etiology. Vincristine / therapeutic use. Vitreous Body / pathology

  • MedlinePlus Health Information. consumer health - Eye Care.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 1984 Jun;81(6):721-7 [6547270.001]
  • [Cites] Cancer Control. 2004 Sep-Oct;11(5):285-95 [15377987.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Feb;11(2):357-64 [3882644.001]
  • [Cites] Am J Clin Oncol. 1992 Jun;15(3):222-5 [1590274.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):843-9 [8334638.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1994 Nov;103(11):911-4 [7979008.001]
  • [Cites] Am J Surg Pathol. 1996 Jan;20(1):103-11 [8540601.001]
  • [Cites] Blood. 1996 Feb 15;87(4):1474-83 [8608238.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 1996 Feb;234(2):137-9 [8720685.001]
  • [Cites] Cancer. 1997 Aug 1;80(3):477-88 [9241082.001]
  • [Cites] Hematol Oncol. 1997 May;15(2):71-9 [9375032.001]
  • [Cites] Ophthalmology. 1998 Aug;105(8):1430-41 [9709754.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2005 May;243(5):482-6 [15586289.001]
  • [Cites] Histopathology. 2005 Nov;47(5):523-32 [16242001.001]
  • [Cites] Leuk Lymphoma. 2005 Dec;46(12):1721-7 [16263574.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Am J Ophthalmol. 2002 Sep;134(3):406-10 [12208253.001]
  • [Cites] Ophthalmology. 1984 Jun;91(6):635-54 [6235470.001]
  • (PMID = 18438613.001).
  • [ISSN] 1573-2630
  • [Journal-full-title] International ophthalmology
  • [ISO-abbreviation] Int Ophthalmol
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 EY000222-22
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Other-IDs] NLM/ NIHMS55130; NLM/ PMC2714878
  •  go-up   go-down


23. Raney B, Anderson J, Breneman J, Donaldson SS, Huh W, Maurer H, Michalski J, Qualman S, Ullrich F, Wharam M, Meyer W, Soft-Tissue Sarcoma Committee of the Children's Oncology Group, Arcadia, California, USA: Results in patients with cranial parameningeal sarcoma and metastases (Stage 4) treated on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols II-IV, 1978-1997: report from the Children's Oncology Group. Pediatr Blood Cancer; 2008 Jul;51(1):17-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results in patients with cranial parameningeal sarcoma and metastases (Stage 4) treated on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols II-IV, 1978-1997: report from the Children's Oncology Group.
  • Primary sites were nasopharynx-nasal cavity, middle ear/mastoid and parapharyngeal area ("better" sites, 55%), paranasal sinus and infratemporal-pterygopalatine area ("worse" sites, 42%), and other (3%).
  • Treatment included vincristine, actinomycin D, and cyclophosphamide (VAC) chemotherapy and radiotherapy to the primary tumor and up to five metastatic sites/tissues.
  • Sixty patients had progressive disease (N = 49) or death as a first event (N = 11); another developed myelodysplastic syndrome and died.
  • Distant metastases were the most frequent type of recurrence, indicating that more effective systemic agents are needed to eliminate residual disease.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18266224.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-98543; United States / NCI NIH HHS / CA / CA-24507; United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / CA-72989; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / CA-29511
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


24. Fitzek MM, Thornton AF, Varvares M, Ancukiewicz M, Mcintyre J, Adams J, Rosenthal S, Joseph M, Amrein P: Neuroendocrine tumors of the sinonasal tract. Results of a prospective study incorporating chemotherapy, surgery, and combined proton-photon radiotherapy. Cancer; 2002 May 15;94(10):2623-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine tumors of the sinonasal tract. Results of a prospective study incorporating chemotherapy, surgery, and combined proton-photon radiotherapy.
  • BACKGROUND: The authors report the results of a prospective study of patients with malignant neuroendocrine tumors of the sinonasal tract who received multimodality treatment incorporating high-dose proton-photon radiotherapy.
  • METHODS: Nineteen patients with olfactory neuroblastoma (ONB) or neuroendocrine carcinoma (NEC) were treated between 1992 and 1998 on a prospective study.
  • Four patients had Kadish Stage B disease, and 15 patients had Kadish Stage C disease.
  • Patients received chemotherapy with 2 courses of cisplatin and etoposide followed by high-dose proton-photon radiotherapy to 69.2 cobalt-Gray equivalents (CGE) using 1.6-1.8 CGE per fraction twice daily in a concomitant boost schedule.
  • Two further courses of chemotherapy were given to responders.
  • RESULTS: Of 19 patients, 15 patients were alive at the time of this report with a median follow-up of 45 months (range, 20-92 months).
  • The 5-year local control rate of initial treatment was 88%.
  • Acute toxicity of chemotherapy was tolerable, with no patient sustaining more than Grade 3 hematologic toxicity.
  • Thirteen patients showed a partial or complete response to chemotherapy.
  • One patient developed unilateral visual loss after the first course of chemotherapy; otherwise, visual preservation was achieved in all patients.
  • Four patients who were clinically intact developed radiation-induced damage to the frontal or temporal lobe by magnetic resonance imaging criteria.
  • Two patients showed soft tissue and/or bone necrosis, and one of these patients required surgical repair of a cerebrospinal fluid leak.
  • CONCLUSIONS: Neoadjuvant chemotherapy and high-dose proton-photon radiotherapy is a successful treatment approach for patients with ONB and NEC.
  • [MeSH-major] Neuroendocrine Tumors / therapy. Nose Neoplasms / therapy. Paranasal Sinus Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Therapy, Combination. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Otorhinolaryngologic Surgical Procedures. Prognosis. Prospective Studies. Radiotherapy, High-Energy. Salvage Therapy

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12173330.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA 21239
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


25. Samant S, Robbins KT, Vang M, Wan J, Robertson J: Intra-arterial cisplatin and concomitant radiation therapy followed by surgery for advanced paranasal sinus cancer. Arch Otolaryngol Head Neck Surg; 2004 Aug;130(8):948-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intra-arterial cisplatin and concomitant radiation therapy followed by surgery for advanced paranasal sinus cancer.
  • OBJECTIVE: To report the long-term efficacy of a combined regimen of intra-arterial high-dose cisplatin chemotherapy and concomitant radiation therapy followed by organ-sparing surgery when possible in the treatment of advanced paranasal sinus cancer.
  • Patients Nineteen patients with advanced paranasal sinus malignancies with a minimum follow-up of 2 years.
  • Malignancies included 14 squamous cell carcinomas (74%), 2 adenocarcinomas (10%), 2 adenoid cystic carcinomas (10%), and 1 undifferentiated carcinoma (5%).
  • Intervention Treatment consisted of preoperative radiation therapy (2.0 Gy/fraction per day; total dose, 50 Gy in 5 weeks) given concomitantly with 3 to 4 weekly infusions of intra-arterial cisplatin (150 mg/m(2) per week) and systemic sodium thiosulfate neutralization.
  • The regimen included planned surgery performed approximately 8 weeks after completion of radiation therapy.
  • One patient died of myocardial infarction during treatment.
  • No other treatment-limiting toxic effect was noted.
  • Except for cataract in 2 patients, no visual loss developed.
  • CONCLUSION: Despite the advanced stage and unfavorable nature of cancer in this cohort, our results indicate that this regimen holds promise and merits further study.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma / therapy. Carcinoma, Adenoid Cystic / therapy. Carcinoma, Squamous Cell / therapy. Cisplatin / therapeutic use. Ethmoid Sinus / pathology. Ethmoid Sinus / surgery. Maxillary Sinus / pathology. Maxillary Sinus / surgery. Paranasal Sinus Neoplasms / therapy. Radiotherapy, Computer-Assisted. Surgical Procedures, Operative
  • [MeSH-minor] Combined Modality Therapy. Disease-Free Survival. Follow-Up Studies. Humans. Infusions, Intra-Arterial. Neoplasm Staging. Postoperative Complications / etiology. Postoperative Complications / mortality. Prospective Studies. Radiation Dosage. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Sinus cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Surgery.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15313865.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


26. Kohno N, Kitahara S: [Chemotherapy for head and neck cancer]. Gan To Kagaku Ryoho; 2000 Feb;27(2):177-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemotherapy for head and neck cancer].
  • Chemotherapy for head and neck cancer was initially used as a palliative treatment in advanced and/or recurrent disease.
  • In a large number of randomized trials, organ function preservation studies have shown the possibility of laryngeal preservation for T2 and T3 laryngeal and hypopharyngeal cancer.
  • A survival benefit has been shown clearly in advanced nasopharyngeal cancer.
  • Another survival prolongation has been demonstrated in cases of locally unresectable cancer in the oral cavity, pharynx, nose and paranasal sinus.
  • Thus, we conclude that neoadjuvant chemotherapy can be effective in cases of locally unresectable cancer in the oral cavity, pharynx, and nose and paranasal sinus.
  • In advanced N stage nasopharyngeal cancer, neoadjuvant chemotherapy plus adjuvant chemotherapy may be indicated.
  • Advanced T stage nasopharyngeal cancer is a good candidate for concurrent chemoradiotherapy.
  • For the aim of laryngeal preservation, neoadjuvant and/or concurrent chemoradiotherapy can be indicated for T2 and T3 laryngeal and hypopharyngeal cancer.
  • [MeSH-major] Evidence-Based Medicine. Head and Neck Neoplasms / drug therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Palliative Care. Randomized Controlled Trials as Topic. Survivors

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10700887.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] JAPAN
  • [Number-of-references] 21
  •  go-up   go-down


27. Xie GF, Cao KJ, Li Y, Huang PY: [Impact of dose boost in skull base on recurrence of stage T4 nasopharyngeal carcinoma]. Ai Zheng; 2005 Oct;24(10):1246-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Impact of dose boost in skull base on recurrence of stage T4 nasopharyngeal carcinoma].
  • BACKGROUND & OBJECTIVE: The recurrence rate in skull base is high for nasopharyngeal carcinoma (NPC) patients with cavernous sinus or/and sphenoid sinus involvement.
  • This study was conducted to explore the impact of dose boost in skull base on the recurrence in skull base and survival of NPC patients with cavernous sinus or/and sphenoid sinus involvement.
  • METHODS: A total of 120 stage T4 NPC patients with cavernous sinus or/and sphenoid sinus involvement proved by histopathology and computed tomography (CT) were treated in our hospital from Oct.
  • The irradiation dose was (71.55+/-3.09) Gy in nasopharynx and (58.95+/-6.16) Gy in neck.
  • Of the 120 patients, 27 received irradiation (6-10 Gy) in skull base after radiotherapy (boost group), 93 did not receive irradiation in skull base (control group).
  • Fifty-three patients, 41 in control group and 12 in boost group, received cisplatin-based chemotherapy for 1-3 cycles.
  • The median disease-freely survival time was longer in boost group than in control group (60 months vs. 30 months).
  • CONCLUSION: Dose boost in skull base can reduce the recurrence of stage T4 NPC in skull base and tends to enhance the disease-freely survival rate for NPC patients with cavernous sinus or/and sphenoid sinus involvementû it is recommended to such patients.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Nasopharyngeal Neoplasms / radiotherapy. Neoplasm Recurrence, Local / prevention & control. Paranasal Sinus Neoplasms / pathology

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16219141.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cobalt Radioisotopes
  •  go-up   go-down


28. Blanch JL, Ruiz AM, Alos L, Traserra-Coderch J, Bernal-Sprekelsen M: Treatment of 125 sinonasal tumors: prognostic factors, outcome, and follow-up. Otolaryngol Head Neck Surg; 2004 Dec;131(6):973-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of 125 sinonasal tumors: prognostic factors, outcome, and follow-up.
  • We reviewed our experience with sinonasal cancer patients to assess the prognostic factors.
  • Tumor stage distribution was: T1, 64 patients; T2, 36 patients; and T3, 25 patients.
  • Surgery as a primary treatment was selected for 106 patients (55 cases of surgery alone, 40 cases of surgery plus radiotherapy, and 11 cases of surgery plus chemotherapy with/without radiotherapy).
  • The parameters with statistical prognostic significance were nodal stage, locoregional failure, and tumor stage.
  • Histological type and primary site had no prognostic value.
  • Radiotherapy seems not to be clearly necessary in stage T1.
  • [MeSH-major] Nasal Cavity. Nose Neoplasms / therapy. Paranasal Sinus Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Otorhinolaryngologic Surgical Procedures. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15577800.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


29. Cheung CW, Burton C, Smith P, Linch DC, Hoskin PJ, Ardeshna KM: Central nervous system chemoprophylaxis in non-Hodgkin lymphoma: current practice in the UK. Br J Haematol; 2005 Oct;131(2):193-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 223 questionnaires were sent to clinicians who administered chemotherapy to patients with NHL; 158 (71%) evaluable questionnaires were returned.
  • The commonest risk factor was site of involvement (paranasal sinus 88%, testicular 85%, orbital cavity 78%, bone marrow 65% and bone 28%).
  • Other risk factors included stage IV, high International Prognostic Index score, >1 extranodal site and raised lactate dehydrogenase levels (34%, 21%, 16% and 10%).
  • A total of 82% did not give prophylaxis in follicular lymphoma and 90% used intrathecal chemotherapy as their preferred method of prophylaxis.
  • The most popular regimen was 12.5 mg methotrexate with each cycle of chemotherapy for six courses.
  • Thirty-nine per cent used systemic chemotherapy for CNS prophylaxis either alone (4%) or as an adjunct to intrathecal prophylaxis (35%).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / prevention & control. Lymphoma, Non-Hodgkin / drug therapy. Patient Selection. Practice Patterns, Physicians'
  • [MeSH-minor] Antibiotic Prophylaxis. Burkitt Lymphoma / drug therapy. Chemoprevention. Great Britain. Humans. Methotrexate / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Risk Factors. Surveys and Questionnaires

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Br J Haematol. 2005 Dec;131(5):673
  • (PMID = 16197449.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down






Advertisement